Top

Published in:

Open Access 01-09-2019 | Chronic Lymphocytic Leukemia | Original Paper

Examination of clonal evolution in chronic lymphocytic leukemia

Authors: Dorota Koczkodaj, Sylwia Popek-Marciniec, Szymon Zmorzyński, Ewa Wąsik-Szczepanek, Agata A. Filip

Published in: Medical Oncology | Issue 9/2019

Abstract

Chronic lymphocytic leukemia (CLL) is one of the most frequent lymphoproliferative diseases. CLL is characterized by unusual heterogeneity, which probably reflects its biological and genetic lack of homogeneity. Clonal chromosome aberrations belong to the most important prognostic and predictive factors in CLL. This research was aimed at observing clonal evolution in CLL at the chromosomal level, and assessing its clinical significance in relation to selected prognostic factors. The study involved 72 untreated patients with CLL. The preliminary investigations using cytogenetic banding analysis (CBA) and FISH were performed at the time of diagnosis, and again after about 24 months to observe clonal changes (clonal evolution). In addition, other parameters were evaluated, i.e., the expression of ZAP-70 kinase, CD38 antigen, and the mutation statuses of IGVH and NOTCH1 genes. Classic prognostic factors, i.e., categorized ZAP70 and CD38 expressions as well as mutations in IGVH and NOTCH1 genes did not influence the course of clonal evolution in the examined group of patients. Clonal evolution was detected in 45.8% of patients by means of CBA, and in 19.4% patients with FISH. Analysis of chromosomal aberrations in the examined group of patients showed that the incidence of 17p deletions and translocations in karyotypes has a negative impact on overall survival. CE was found to be a risk factor for the occurrence of disease progression (OR = 2.22). Our observations indicate that combined CBA and FISH are the most optimal techniques for monitoring clonal evolution in the course of CLL.

Dighiero G. CLL biology and prognosis. Hematol Am Soc Hematol Educ Program. 2005;2005:278–84. https://doi.org/10.1182/asheducation-2005.1.278.CrossRef

Rai K, Jain P. Chronic lymphocytic leukemia (CLL)—then and now. AM J Haematol. 2016;91(3):330–40. https://doi.org/10.1002/ajh.24282.CrossRef

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.CrossRefPubMed

Eichhorst B, Hallek M. Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematol Am Soc Hematol Educ Program. 2016;2016:149–55.CrossRef

Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S, Laurenti L, Marasca R, Rasi S, Fangazio M, Guarini A, Gaidano G, Foa R. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica. 2012;97:437–41. https://doi.org/10.3324/haematol.2011.060129.CrossRefPubMedPubMedCentral

Finn WG, Kay NE, Kroft SH, Church S, Peterson LC. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. Am J Hematol. 1998;59:223–9.CrossRefPubMed

Juliusson G, Oscier D, Gahrton G, for the International Working Party On Chromosomes In CLL (IWCCLL). Cytogenetic findings and survival in B-cell chronic lymphocytic Leukemia. Second IWCCLL compilation of date on 662 patients. Leukemia Lymph. 1991;5:21–5.CrossRef

Bercova A, Zemanova Z, Trneny M, Schwartz J, Karban J, Cmunt E, Pavlistova L, Brezinova J, Michalova K. Clonal evolution In chronic lymphocyytic leukemia studied by interphase fluorescence in situ hybridization. Neoplasma. 2009;56(5):455–8.CrossRef

Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL a study on 506 cases analyzed with chromosome banding analysis, interphase FISH, IGVH status and immunophenotyping. Leukemia. 2007;21:2442–51. https://doi.org/10.1038/sj.leu.2404935.CrossRefPubMed

10.

Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med. 2000;343:1910–6. https://doi.org/10.1056/nejm200012283432602.CrossRef

11.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018. https://doi.org/10.1182/blood-2017-09-806398.CrossRefPubMed

12.

López C, Delgado J, Costa D, Villamor N, Navarro A, Cazorla M, Gómez C, Arias A, Muñoz C, Cabezas S, Baumann T, Rozman M, Aymerich M, Colomer D, Pereira A, Cobo F, López-Guillermo A, Campo E, Carrió A. Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. Genes Chromosomes Cancer. 2013;52(10):920–7. https://doi.org/10.1002/gcc.22087.CrossRefPubMed

13.

Koczkodaj D, Popek S, Zmorzyński S, Wąsik-Szczepanek E, Filip AA. Detection of chromosomal changes in chronic lymphocytic leukemia using classical cytogenetic methods and FISH: application of rich mitogen mixtures for lymphocyte cultures. J Invest Med. 2016;64:894–8. https://doi.org/10.1136/jim-2015-000050.CrossRef

14.

McGowan-Jordan J, Simons A, Schmid M, eds. ISCN 2016: An International System for Human Cytogenomic Nomenclature. Basel (Switzerland) Karger 2016 ISBN 978-3-318-05857-4.

15.

Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506–10. https://doi.org/10.1038/nature10738.CrossRefPubMedPubMedCentral

16.

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92. https://doi.org/10.1056/nejmoa1113205.CrossRefPubMedPubMedCentral

17.

Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, Louis DN, Iafrate AJ. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6):810–7. https://doi.org/10.1016/j.ccr.2011.11.005.CrossRefPubMed

18.

Schuh A, Becq J, Humphray S, Alexa A, Burns A, Clifford R, Feller SM, Grocock R, Henderson S, Khrebtukova I, Kingsbury Z, Luo S, McBride D, Murray L, Menju T, Timbs A, Ross M, Taylor J, Bentley D. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120:4191–6. https://doi.org/10.1182/blood-2012-05-433540.CrossRefPubMed

19.

Wu CJ. CLL clonal heterogeneity: an ecology of competing subpopulations. Blood. 2012;120(20):4117–8. https://doi.org/10.1182/blood-2012-09-452805.CrossRefPubMed

20.

Cotter M, Auer RL. Genetic alterations associated with chronic lymphocytic leukemia. Cytogenet Genome Res. 2007;118:310–9. https://doi.org/10.1159/000108315.CrossRefPubMed

21.

Dubuc A, Davids M, Pulluqi M, Hoang K, Hernandez-Sanchez J, Schlich C, Hernandez-Rivas M, Brown J, Dal Cin P. FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. Am J Hematol. 2016;91(10):978–83. https://doi.org/10.1002/ajh.24452.CrossRefPubMed

22.

23.

Loscertales J, Arranz E, Sanz MA, Blas C, Gil-Fernández JJ, Burgaleta C, Alegre A. Clonal evolution in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51:1142–3. https://doi.org/10.3109/10428191003793374.CrossRefPubMed

24.

Wawrzyniak E, Kotkowska A, Błoński JZ, Semeniuk-Ryś M, Ziółkowska E, Giannopoulos K, Robak T, Korycka-Wołowiec A. Clonal evolution In CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance. Eur J Haematol. 2013;92:91–101. https://doi.org/10.1111/ejh.12215.CrossRefPubMed

25.

Fegan C, Robinson H, Thompson P, Whittaker JA, White D. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia. 1995;9:2003–8.PubMed

26.

27.

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K, ERIC, the European Research Initiative on CLL. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205–16. https://doi.org/10.1182/blood-2018-09-873083.CrossRefPubMedPubMedCentral

28.

Rigolin GM, del Giudice I, Formigaro L, Saccenti E, Martinelli S, Cavallari M, Lista E, Tammiso E, Volta E, Lupini L, Bassi C, Bardi A, Sofritti O, Daghia G, Cavazzini F, Marinelli M, Tavolaro S, Guarini A, Negrini M, Foà R, Cuneo A. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: clinical and biologic correlations. Genes Chromosomes Cancer. 2015;54:818–26. https://doi.org/10.1002/gcc.22293.CrossRefPubMed

29.

Janssens A, Van Roy N, Poppe B, Noens L, Philippé J, Speleman F, Offner F. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature. Eur J Haematol. 2012;89:72–80. https://doi.org/10.1111/j.1600-0609.2012.01790.CrossRefPubMed

30.

Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, Kröber A, Kienle D, Lichter P, Döhner H. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92:1242–5.CrossRefPubMed

31.

32.

Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016;127(14):1752–60. https://doi.org/10.1182/blood-2015-10-620864.CrossRefPubMed

33.

Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92:375–80. https://doi.org/10.1002/ajh.24660.CrossRefPubMed

34.

Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A, Spina V, Deambrogi C, Marinelli M, Famà R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foà R, Gaidano G. Disruption of BICR1 associates with fludarabine chemorefractioriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119:2854–62. https://doi.org/10.1182/blood-2011-12-395673.CrossRefPubMed

35.

Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell’Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011;305(1):59–67. https://doi.org/10.1001/jama.2010.1919.CrossRefPubMedPubMedCentral

36.

Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, Jares P, Bea S, Gonzalez-Diaz M, Bassaganyas L, Baumann T, Juan M, Lopez-Guerra M, Colomer D, Tubio JM, Lopez C, Navarro A, Tornador C, Aymerich M, Rozman M, Hernandez JM, Puente DA, Freije JM, Velasco G, Gutierrez-Fernandez A, Costa D, Carrio A, Guijarro S, Enjuanes A, Herandez L, Yague J, Nicolas P, Romeo-Casabona CM, Himmelbauer H, Castillo E, Dohm JC, de Sanjose S, Piris MA, de Alava E, San Miguel J, Royo R, Gelpi JL, Torrentes D, Orozco M, Pisano DG, Valencia A, Guigo R, Bayes M, Heath S, Gut M, Klatt P, Marshall J, Raine K, Stebbings LA, Futreal PA, Stratton MR, Campbell PJ, Gut I, Lopez-Guillermo A, Estivill X, Monserrat E, Loez-Otin C, Campo E. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–5. https://doi.org/10.1038/nature10113.CrossRefPubMedPubMedCentral

37.

Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119:329–31. https://doi.org/10.1182/blood-2011-10-386144.CrossRefPubMedPubMedCentral

38.

Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, Sutton L, Lesty C, Merle-Béral H, Cymbalista F, Ysebaert L, Davi F, Leblond V, FILO working group. Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: a retrospective study from the French Innovative Leukemia Organization (FILO) working group. Genes Chromosomes Cancer. 2018;57:533–40. https://doi.org/10.1002/gcc.22650.CrossRefPubMed

39.

Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NC, Catovsky D, Strefford JC. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013;121:468–75. https://doi.org/10.1182/blood-2012-05-429282.CrossRefPubMed

40.

Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–30. https://doi.org/10.1038/nature15395.CrossRefPubMedPubMedCentral

41.

Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526:519–24. https://doi.org/10.1038/nature14666.CrossRefPubMed

42.

43.

López C, Delgado J, Costa D, Villamor N, Navarro A, Cazorla M, Gómez C, Arias A, Muñoz C, Cabezas S, Baumann T, Rozman M, Aymerich M, Colomer D, Pereira A, Cobo F, López-Guillermo A, Campo E, Carrió A. Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. Genes Chromosomes Cancer. 2013;52:920–7. https://doi.org/10.1002/gcc.22087.CrossRefPubMed

44.

Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;10:24004. https://doi.org/10.1002/cncr.24004.CrossRef

45.

Rodríguez-Vicente AE, Bikos V, Hernández-Sánchez M, Malcikova J, Hernández-Rivas JM, Pospisilova S. Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. Oncotarget. 2017;8:71234–48. https://doi.org/10.18632/oncotarget.19525.CrossRefPubMedPubMedCentral

Title: Examination of clonal evolution in chronic lymphocytic leukemia
Authors: Dorota Koczkodaj
Sylwia Popek-Marciniec
Szymon Zmorzyński
Ewa Wąsik-Szczepanek
Agata A. Filip
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Chronic Lymphocytic Leukemia
Chromosomal Abnormality
Trisomy
Published in: Medical Oncology / Issue 9/2019
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-019-1300-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Examination of clonal evolution in chronic lymphocytic leukemia

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2019

ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer

Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis

MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy

EMT-related protein expression in polyploid giant cancer cells and their daughter cells with different passages after triptolide treatment

Identification of important invasion and proliferation related genes in adrenocortical carcinoma

A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page